Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Nanjing Livingchip Biotechnology Co. Ltd. manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area. Currently, the portfolio has 1 pending office action. This action represents the current level of active engagement with the patent office for the company's biotechnological filings. For a practitioner, this indicates a focused prosecution stage where a single application is the primary administrative priority.
The filings are being reviewed by a distinct examiner across a single art unit. This suggests that the company's innovations are being evaluated through a single administrative channel at the USPTO. MIANO, JOSEPH PAUL is the busiest examiner for the portfolio. The use of a single art unit ensures that the company's biotechnological technologies are evaluated against a consistent set of prior art and examination standards.
MIANO, JOSEPH PAUL is responsible for 1 busiest examiner pending office action. Since there is only a single pending action overall, the review by MIANO, JOSEPH PAUL is the sole focus of the company's current patenting activity. Practitioners should tailor their strategy to the specific requirements of MIANO, JOSEPH PAUL and the art unit involved to advance the pending matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MIANO, JOSEPH PAUL | 1 | 35.7% | +63.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18156597 | METHOD FOR SCREENING FOR TARGET CELLS OR CELLS, AND BIOLOGICAL CULTURE CHIP | MIANO, JOSEPH PAUL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18156597 | METHOD FOR SCREENING FOR TARGET CELLS OR CELLS, AND BIOLOGICAL CULTURE CHIP | MIANO, JOSEPH PAUL | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18156597 | METHOD FOR SCREENING FOR TARGET CELLS OR CELLS, AND BIOLOGICAL CULTURE CHIP | MIANO, JOSEPH PAUL | 1631 | §102§103 | Final Rejection | — | Pending | Jan 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNanjing Livingchip Biotechnology Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Joseph Paul Miano has the most, with 1 of Nanjing Livingchip Biotechnology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
